Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NETTER-2 first-line Lutathera in advanced GEP-NET
2023-507443-10-00Phase 3Authorised
- Sponsor
- Advanced Accelerator Applications
- Start
- Nov 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor (2 arms), sponsored by Advanced Accelerator Applications. Primary endpoint: Progression-free survival. Planned start Nov 2019; status: authorised.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on 2023-507443-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507443-10-00.